Q-omics provides the consensus-scored CCDC34 profile across patient tissues and cancer cell-line models. CCDC34 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCDC34 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CCDC34 RNA expression shows 20,551 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where CCDC34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC34 survival associations across molecular data types. CCDC34 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC34 RNA expression–survival associations across cancer types. High CCDC34 expression shows unfavorable associations in LIHC, KIRC, LGG and ACC, but favorable associations in BRCA and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCDC34 RNA expression.
This table summarizes CCDC34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC34 shows higher tumor expression in KIRC, BLCA, KIRP, STAD, LUSC and LIHC. The KIRC box plot shows higher CCDC34 RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with CCDC34 in patient tissues and cancer cell lines. In patient samples, CCDC34 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
